COMPARISON OF INTERFERON-GAMMA RELEASE ASSAY VERSUS TUBERCULIN SKIN TEST FOR LATENT TUBERCULOSIS SCREENING IN HEMODIALYSIS PATIENTS

Basit Öğe Kaydı
dc.contributor.authorAtes, G.
dc.contributor.authorOzekinci, T.
dc.contributor.authorYildiz, T.
dc.contributor.authorDanis, R.
dc.date.accessioned2024-04-24T17:07:44Z
dc.date.available2024-04-24T17:07:44Z
dc.date.issued2009
dc.departmentDicle Üniversitesien_US
dc.description.abstractEarly diagnosis and proper treatment of latent tuberculosis infection (LTB1) in patients with end stage renal diseases (ESRD) is critical to reduce increased reactivation risk of LTB1. However; this condition is known to decrease responsiveness to the tubercidin skin test (TST). A new, diagnostic test [QuantiFERON-TB Gold in-tube (QFT-GIT)] has been developed using mycobacterium tuberculosis specific antigens for the identification of LTB1. We aimed to evaluate the two test methods among hemodialysis patients for their diagnostic usefulness. We performed a cross-sectional comparison study on 275 ESRD recruits tested for LTB1 using the TST and QTF-GIT. Valid TST and QFT-GIT results were available for 259 and 246 patients, respectively. Overall, 46.7% of 246 patients were tested positive for the QTF-GIT and 35.5% of 259 were found to be TST positive. The QTF-GIT but not TST results were correlated with the history of tuberculosis: conversely, QTF-GIT and TST results were not associated with contact to tuberculosis. Moreover, QTF-GIT test generated indeterminate results in 10.4% of subjects. The concurrence between the two test methods was poor (67.8%, kappa = 0.34). Inconsistent results, most of which were, tested as TST negative/QTF-GIT positive were observed in 32.2% patients. The present results suggest that the QTF-GIT is more sensitive than TST in the detection of LTB1 among renal dialysis patients. Nevertheless, large longitudinal studies are required for more accurate results.en_US
dc.description.sponsorshipUniversity of Dicleen_US
dc.description.sponsorshipThis study was funded by a grant from University of Dicle. The authors would like to thank Dr. Fesih Azboy and Adil Alp from the Office of TB Control at the Government Health Department at Diyarbakir for their assistance in this investigation.en_US
dc.identifier.doi10.1080/13102818.2009.10817646
dc.identifier.endpage1246en_US
dc.identifier.issn1310-2818
dc.identifier.issn1314-3530
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-76449114863
dc.identifier.scopusqualityQ3
dc.identifier.startpage1242en_US
dc.identifier.urihttps://doi.org/10.1080/13102818.2009.10817646
dc.identifier.urihttps://hdl.handle.net/11468/16941
dc.identifier.volume23en_US
dc.identifier.wosWOS:000266375300016
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofBiotechnology & Biotechnological Equipment
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLatent Tuberculosisen_US
dc.subjectTuberculosisen_US
dc.subjectInterferon Gammaen_US
dc.subjectDialysisen_US
dc.subjectRenal Failureen_US
dc.titleCOMPARISON OF INTERFERON-GAMMA RELEASE ASSAY VERSUS TUBERCULIN SKIN TEST FOR LATENT TUBERCULOSIS SCREENING IN HEMODIALYSIS PATIENTSen_US
dc.titleCOMPARISON OF INTERFERON-GAMMA RELEASE ASSAY VERSUS TUBERCULIN SKIN TEST FOR LATENT TUBERCULOSIS SCREENING IN HEMODIALYSIS PATIENTS
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu